PT86621B - Processo para a preparacao de sais derivados de rifamicina e de composicoes farmaceuticas que os contem - Google Patents
Processo para a preparacao de sais derivados de rifamicina e de composicoes farmaceuticas que os contem Download PDFInfo
- Publication number
- PT86621B PT86621B PT86621A PT8662188A PT86621B PT 86621 B PT86621 B PT 86621B PT 86621 A PT86621 A PT 86621A PT 8662188 A PT8662188 A PT 8662188A PT 86621 B PT86621 B PT 86621B
- Authority
- PT
- Portugal
- Prior art keywords
- organic base
- pharmaceutical compositions
- rifamycin
- inorganic
- preparation
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 15
- 238000000034 method Methods 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 229930189077 Rifamycin Natural products 0.000 title description 3
- 229960003292 rifamycin Drugs 0.000 title description 2
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 title 1
- 150000007530 organic bases Chemical class 0.000 claims abstract description 5
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 4
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 150000007529 inorganic bases Chemical group 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 206010062207 Mycobacterial infection Diseases 0.000 abstract 1
- -1 Rifamycin derivative salts Chemical class 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 150000001767 cationic compounds Chemical class 0.000 abstract 1
- 229910001411 inorganic cation Inorganic materials 0.000 abstract 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- YVOFSHPIJOYKSH-NLYBMVFSSA-M sodium rifomycin sv Chemical class [Na+].OC1=C(C(O)=C2C)C3=C([O-])C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O YVOFSHPIJOYKSH-NLYBMVFSSA-M 0.000 description 5
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 4
- 229960001225 rifampicin Drugs 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical group O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT19162/87A IT1202424B (it) | 1987-01-26 | 1987-01-26 | Sali di un derivato rifamicinico |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT86621A PT86621A (pt) | 1988-02-01 |
| PT86621B true PT86621B (pt) | 1991-12-31 |
Family
ID=11155406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT86621A PT86621B (pt) | 1987-01-26 | 1988-01-26 | Processo para a preparacao de sais derivados de rifamicina e de composicoes farmaceuticas que os contem |
Country Status (7)
| Country | Link |
|---|---|
| KR (1) | KR960006393B1 (en, 2012) |
| CN (1) | CN1015368B (en, 2012) |
| ES (1) | ES2006280A6 (en, 2012) |
| GB (1) | GB2200353B (en, 2012) |
| IN (1) | IN165924B (en, 2012) |
| IT (1) | IT1202424B (en, 2012) |
| PT (1) | PT86621B (en, 2012) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0447813A1 (en) * | 1990-02-28 | 1991-09-25 | GRUPPO LEPETIT S.p.A. | Water soluble salts of purpuromycin and pharmaceutical formulations thereof |
| BG64021B1 (bg) * | 1998-11-04 | 2003-10-31 | КОНСТАНТИНОВА Румяна | Натриева сол на 3-(4-цинамил-1-пиперазинил)-иминометил рифамицин и метод за получаването й |
| BR112015002945B1 (pt) * | 2012-08-13 | 2021-08-31 | Adipharm Ead | Formulações farmacêuticas contendo derivados de 3-(4-cinamil-1-piperazinil)-amino de 3- formil-rifamicina sv e 3-formil-rifamicina s e um processo para sua preparação |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1201963B (it) * | 1983-03-24 | 1989-02-02 | Prodotti Antibiotici Spa | Derivati delle rifamicine e procedimento per la loro preparazione |
-
1987
- 1987-01-26 IT IT19162/87A patent/IT1202424B/it active
-
1988
- 1988-01-18 IN IN44/CAL/88A patent/IN165924B/en unknown
- 1988-01-25 KR KR1019880000536A patent/KR960006393B1/ko not_active Expired - Fee Related
- 1988-01-25 GB GB8801577A patent/GB2200353B/en not_active Expired - Fee Related
- 1988-01-26 ES ES8800204A patent/ES2006280A6/es not_active Expired
- 1988-01-26 PT PT86621A patent/PT86621B/pt not_active IP Right Cessation
- 1988-01-26 CN CN88100328A patent/CN1015368B/zh not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ES2006280A6 (es) | 1989-04-16 |
| IN165924B (en, 2012) | 1990-02-10 |
| GB8801577D0 (en) | 1988-02-24 |
| CN88100328A (zh) | 1988-09-28 |
| IT1202424B (it) | 1989-02-09 |
| GB2200353A (en) | 1988-08-03 |
| KR880009026A (ko) | 1988-09-13 |
| KR960006393B1 (ko) | 1996-05-15 |
| CN1015368B (zh) | 1992-02-05 |
| GB2200353B (en) | 1990-11-28 |
| IT8719162A0 (it) | 1987-01-26 |
| PT86621A (pt) | 1988-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2622356T3 (es) | Formas cristalinas de tigeciclina y procesos para su preparación | |
| CN113476469B (zh) | 抗微生物化合物、组合物及其用途 | |
| HU189586B (en) | Process for preparing crystalline salts of benzothiazine-dioxide | |
| US6503929B1 (en) | Nitrate salt of anti-ulcer medicine | |
| CA1188305A (en) | Ester of metronidazole with n,n-dimethylglycine and acid addition salt thereof | |
| PT86621B (pt) | Processo para a preparacao de sais derivados de rifamicina e de composicoes farmaceuticas que os contem | |
| US4418060A (en) | Therapeutically active complexes of tetracyclines | |
| JPS6248678B2 (en, 2012) | ||
| JPH03503162A (ja) | 化学療法における毒性特性の改良 | |
| EP0869117B1 (en) | Nimesulide choline salt, a process for the preparation thereof and pharmaceutical compositions containing it | |
| JPH03128380A (ja) | Ｎ↑５，ｎ↑１↑０―メチレン―５，６，７，８―テトラヒドロ葉酸の塩およびその製造方法 | |
| CN112778364B (zh) | 一种硝基咪唑类衍生物及其制备方法和用途 | |
| PT812320E (pt) | Firetanido amorfo piretanido polimorfo processo para a sua preparacao e sua utilizacao | |
| EP0923932B1 (en) | Composition containing antitumor agent | |
| KR860000450B1 (ko) | α-6-데옥씨-5-하이드록씨 테트라 싸이클린과 소듐 테트라메타포스 페이트의 수용성 복합체의 제조방법 | |
| KR830002533B1 (ko) | 수용성 3-포르밀리파미이신 sv 하이드라존의 제조방법 | |
| JPH0742287B2 (ja) | ２−アミノアルキル−９−ヒドロキシエリプテイシニウム誘導体のクロライドの塩酸塩及びそれを含む医薬 | |
| US4005214A (en) | Water-soluble amoxicillin salts | |
| US4322424A (en) | Crystalline glucoconate salt of m-AMSA and compositions containing same | |
| BG64021B1 (bg) | Натриева сол на 3-(4-цинамил-1-пиперазинил)-иминометил рифамицин и метод за получаването й | |
| US3524845A (en) | Process for the manufacture of 3-formylrifamycin-sv | |
| KR100344099B1 (ko) | 신규한비페닐디카르복실산유도체와이의제조방법 | |
| CA1159368A (en) | Antitumor compositions | |
| JPH0315632B2 (en, 2012) | ||
| JPH01132525A (ja) | 抗ウイルス及び抗腫瘍効果を有する、動物及び人間用の治療薬の製造方法、並びに該方法によって得られる薬剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM3A | Annulment or lapse |
Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20031231 |